) shares fell in after-hours trading due to a disappointing outlook. Analyst James Hardiman joins Yahoo Finance Live to weigh in on the results. Hardiman says the issue for investors isn't Barbie excitement dying down, but rather"a lot of investors are trying to look at their business, sort of, ex-Barbie so that we can try to figure out what earnings power looks like for 2024.
Pfizer will still benefit from the 25% stake it retained as well as full rights to the drug outside the US and Japan. If AI Is Indeed the 4th Industrial Revolution, You’ll Want to Buy These Stocks Sooner Rather Than Later
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: